By Lina carolina 
A groundbreaking pan-Canadian initiative has unveiled a revolutionary method for swiftly identifying personalized treatments for young cancer patients. This innovative approach involves cultivating patient-specific tumors within chicken eggs and meticulously analyzing their protein profiles. This pioneering work, spearheaded by a collaborative team from the University of British Columbia (UBC) and the BC Children’s Hospital Research Institute (BCCHR), marks the first instance in Canada where these two advanced techniques have been successfully integrated to diagnose and test a drug for a young patient’s tumor in a timeframe conducive to immediate treatment. The findings, detailed in the prestigious journal EMBO Molecular Medicine, underscore the significant potential of proteomics, the study of proteins, as a powerful complement to genomics, the study of genes, in the realm of real-time cancer therapies.
The PROFYLE Initiative: A National Network for Pediatric Cancer Advancement
This significant breakthrough is a direct product of PROFYLE (PRecision Oncology For Young peopLE), a cornerstone initiative within the Canadian pediatric cancer network ACCESS (Advancing Childhood Cancer Experience, Science and Survivorship). PROFYLE represents a monumental collaborative effort, uniting over 30 research and funding organizations and more than 100 investigators from across Canada. Its overarching mission is to dramatically improve cancer outcomes for children and young adults, a demographic often underserved by traditional cancer research focused primarily on adult populations. The network’s commitment to fostering interdisciplinary collaboration and sharing resources has been instrumental in driving forward this novel treatment strategy.
A Complex Case: Tackling a Rare and Resistant Pediatric Cancer
The study that illuminated this new path focused on an unnamed pediatric patient diagnosed with a rare and aggressive form of cancer that had proven stubbornly resistant to all conventional treatment modalities. The co-lead authors of the study, Dr. Georgina Barnabas, a postdoctoral researcher working under the supervision of Dr. Philipp Lange, and Tariq Bhat, a PhD student in Dr. James Lim’s laboratory, dedicated their efforts to finding a viable therapeutic avenue for this challenging case.
Proteomics: Unveiling Hidden Therapeutic Targets
The fundamental principle behind this research lies in understanding the distinct roles of genes and proteins within the body. Genes, often referred to as the blueprints of life, provide the instructions for building proteins. However, it is proteins that are the true workhorses of our cells, carrying out the vast majority of biological functions. Most cancer drugs are designed to interfere with the activity of specific proteins, thereby disrupting tumor growth and survival. Recognizing this, the research team hypothesized that a deeper analysis of the tumor’s protein landscape – proteomics – might reveal vulnerabilities that genetic analysis alone might overlook.
While genomic testing is a standard and valuable tool in cancer diagnosis and treatment selection, it primarily focuses on identifying genetic mutations. In this particular patient’s case, after standard chemotherapy had proven ineffective and the tumor developed resistance to a drug previously selected based on genomic profiling, no clear drug candidates emerged from further genetic investigations. This presented a critical juncture where traditional approaches reached their limitations.
It was at this point that the team pivoted to a proteomic analysis. This comprehensive study of the tumor’s protein composition revealed a critical metabolic dependency: the tumor’s survival relied heavily on the activity of a specific enzyme known as SHMT2 (serine hydroxymethyltransferase 2). This enzyme plays a crucial role in folate metabolism, a pathway essential for cell growth and division, particularly in rapidly proliferating cancer cells.
"With genomics alone, we couldn’t find a clear treatment option," explained Dr. Philipp Lange, a senior investigator with the Michael Cuccione Childhood Cancer Research Program at BCCHR. Dr. Lange, alongside Dr. James Lim and clinician Dr. Rebecca Deyell, formed the senior leadership of this critical research program. "But by looking at the tumour’s proteins, we found a critical metabolic weakness that we could target with an already approved drug."
Repurposing an Antidepressant: A Novel Therapeutic Strategy
The discovery of the tumor’s reliance on SHMT2 opened up a novel therapeutic avenue. The researchers identified that sertraline, a widely available and commonly prescribed antidepressant medication, acts as an inhibitor of SHMT2. By blocking the activity of this enzyme, sertraline could potentially disrupt the tumor’s access to a vital energy source, thereby hindering its growth. This strategy represents a prime example of drug repurposing, where an existing medication approved for one condition is investigated for efficacy in treating another, often with the advantage of established safety profiles and faster regulatory pathways.
The Chicken Egg Avatar: Accelerating Treatment Evaluation
The critical next step was to validate whether sertraline could indeed effectively target the patient’s specific tumor. Traditional drug testing methods, such as laboratory cell cultures or animal models, can be time-consuming, often taking months to yield results. For a child with a rapidly progressing and treatment-resistant cancer, such a delay is simply not an option.
To overcome this temporal challenge, the researchers employed a cutting-edge technique: growing a small sample of the patient’s tumor within a chicken egg. The developing embryo and its supportive structures within the egg provide a remarkably accurate and rapid "avatar" host for the tumor. This ex vivo cultivation of an identical tumor outside the patient’s body allowed the research team to test the efficacy of sertraline in a matter of weeks.
"This technique speeds up the process of evaluating a treatment option in a way that simply wouldn’t be possible with traditional methods," stated Dr. James Lim, emphasizing the transformative nature of this approach. "We could quickly confirm whether the drug we identified through proteomics could actually work for the patient’s tumour."
These chicken egg avatars are a key component of the BRAvE initiative (Better Responses through Avatars and Evidence) at BCCHR. BRAvE is designed to create a seamless link between clinical care in hospital settings and the innovative research conducted in the hospital’s laboratories, fostering a dynamic cycle of discovery and application.
Expert Review and Treatment Decision
Once the in-egg testing provided promising results, the research team presented their comprehensive findings to a panel of experts established by PROFYLE. This multidisciplinary panel, comprising oncologists, researchers, and pharmacologists, meticulously reviewed the data. Based on the evidence generated through proteomics and the chicken egg avatar model, sertraline was identified as the most promising treatment option for the patient at that critical juncture.
Promising Outcomes, Yet Continued Research
The implementation of sertraline treatment yielded encouraging results. The patient’s tumor growth demonstrably slowed, indicating a positive response to the targeted therapy. However, it is crucial to note that the treatment did not result in a complete remission, highlighting the complex and often multi-faceted nature of pediatric cancers. Additional therapeutic interventions were still deemed necessary to achieve a more definitive outcome.
"While there is more work to be done, this study shows that our approach can deliver personalized treatment recommendations fast enough to actually help patients with rare and difficult-to-treat cancers," Dr. Lange remarked, underscoring the immediate clinical impact of their methodology. "We now hope to expand this method to other children to identify effective treatments faster across the country."
Broader Implications and Future Directions
The success of this pan-Canadian collaboration has profound implications for the future of pediatric oncology. It validates the power of integrating advanced proteomic analysis with innovative in vivo modeling techniques, such as chicken egg avatars, to accelerate the discovery of personalized therapies. This approach holds immense promise for children diagnosed with rare cancers, those with tumors that are genetically difficult to profile, or patients whose cancers have become resistant to standard treatments.
The ability to rapidly identify and test drug candidates can significantly shorten the "diagnostic odyssey" many young patients endure, reducing the time spent on ineffective treatments and minimizing exposure to toxic therapies. Furthermore, the successful repurposing of a widely available drug like sertraline suggests that this methodology could lead to more accessible and cost-effective treatment options.
Looking ahead, the researchers aim to expand this integrated approach to a larger cohort of pediatric cancer patients across Canada. This will involve refining the proteomic profiling techniques, further optimizing the chicken egg avatar model, and strengthening the collaborative network through initiatives like PROFYLE and ACCESS. The ultimate goal is to establish a robust and scalable platform that can deliver rapid, personalized treatment recommendations for every child battling cancer, thereby improving survival rates and enhancing the quality of life for young patients and their families nationwide. This groundbreaking research represents a significant leap forward in the quest for precision medicine in pediatric oncology, offering a beacon of hope for those facing the most challenging forms of cancer.
